c-Kit-Targeting Immunotherapy for Hereditary Melanoma in a Mouse Model

Masashi Kato, Kozue Takeda, Yoshiyuki Kawamoto, Toyonori Tsuzuki, Khaled Hossain, Akiko Tamakoshi, Takahiro Kunisada, Yasuhiro Kambayashi, Keiki Ogino, Haruhiko Suzuki, Masahide Takahashi, Izumi Nakashima

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The role of c-Kit in the development of melanoma was studied in line 304/ B6 of RET-transgenic mice, in which melanoma spontaneously develops. In Wv/Wv-RET (304/B6)-transgenic mice, in which c-Kit function was severely impaired, development of melanoma was strongly suppressed. Although 31 of the 44 original RET-transgenic mice died of rapidly growing melanoma within 12 months after birth, only 8 of the 44 Wv/Wv-RET-transgenic mice developed slowly growing melanocytic tumors with a greatly prolonged mean tumor-free period, 2 of which died of melanoma at a late stage. Even Wv/+-RET-transgenic mice had a clearly prolonged tumor-free period and definitely reduced frequency (6 of 61) of tumor death within 12 months after birth. Melanin production in the skin of these mice was not strongly impaired, suggesting that c-Kit affects the development of melanomas in these mice with only minor effects in melanin production. c-Kit expression in skin soon after birth was promoted in RET-transgenic mice, and c-Kit was expressed at high levels at the benign but not malignant stage of the tumor. A single injection of anti-c-Kit antibody (ACK2) into RET-transgenic mice soon after birth caused a surprisingly long-lasting suppression of development of melanoma, greatly prolonging the tumor-free period, and none of the 28 ACK2-treated RET-transgenic mice died from tumors at 12 months of age. The c-Kit function needed for melanin production was also suppressed for an unusually long time in ACK2-treated, RET-transgenic mice. These results suggest that c-Kit can be a unique target molecule for melanoma treatment.

Original languageEnglish
Pages (from-to)801-806
Number of pages6
JournalCancer Research
Volume64
Issue number3
DOIs
Publication statusPublished - Feb 1 2004
Externally publishedYes

Fingerprint

Immunotherapy
Transgenic Mice
Melanoma
Melanins
Neoplasms
Parturition
Skin
Injections

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kato, M., Takeda, K., Kawamoto, Y., Tsuzuki, T., Hossain, K., Tamakoshi, A., ... Nakashima, I. (2004). c-Kit-Targeting Immunotherapy for Hereditary Melanoma in a Mouse Model. Cancer Research, 64(3), 801-806. https://doi.org/10.1158/0008-5472.CAN-03-2532

c-Kit-Targeting Immunotherapy for Hereditary Melanoma in a Mouse Model. / Kato, Masashi; Takeda, Kozue; Kawamoto, Yoshiyuki; Tsuzuki, Toyonori; Hossain, Khaled; Tamakoshi, Akiko; Kunisada, Takahiro; Kambayashi, Yasuhiro; Ogino, Keiki; Suzuki, Haruhiko; Takahashi, Masahide; Nakashima, Izumi.

In: Cancer Research, Vol. 64, No. 3, 01.02.2004, p. 801-806.

Research output: Contribution to journalArticle

Kato, M, Takeda, K, Kawamoto, Y, Tsuzuki, T, Hossain, K, Tamakoshi, A, Kunisada, T, Kambayashi, Y, Ogino, K, Suzuki, H, Takahashi, M & Nakashima, I 2004, 'c-Kit-Targeting Immunotherapy for Hereditary Melanoma in a Mouse Model', Cancer Research, vol. 64, no. 3, pp. 801-806. https://doi.org/10.1158/0008-5472.CAN-03-2532
Kato M, Takeda K, Kawamoto Y, Tsuzuki T, Hossain K, Tamakoshi A et al. c-Kit-Targeting Immunotherapy for Hereditary Melanoma in a Mouse Model. Cancer Research. 2004 Feb 1;64(3):801-806. https://doi.org/10.1158/0008-5472.CAN-03-2532
Kato, Masashi ; Takeda, Kozue ; Kawamoto, Yoshiyuki ; Tsuzuki, Toyonori ; Hossain, Khaled ; Tamakoshi, Akiko ; Kunisada, Takahiro ; Kambayashi, Yasuhiro ; Ogino, Keiki ; Suzuki, Haruhiko ; Takahashi, Masahide ; Nakashima, Izumi. / c-Kit-Targeting Immunotherapy for Hereditary Melanoma in a Mouse Model. In: Cancer Research. 2004 ; Vol. 64, No. 3. pp. 801-806.
@article{e59eb1e0ed674c0caaf5495aacd97d9f,
title = "c-Kit-Targeting Immunotherapy for Hereditary Melanoma in a Mouse Model",
abstract = "The role of c-Kit in the development of melanoma was studied in line 304/ B6 of RET-transgenic mice, in which melanoma spontaneously develops. In Wv/Wv-RET (304/B6)-transgenic mice, in which c-Kit function was severely impaired, development of melanoma was strongly suppressed. Although 31 of the 44 original RET-transgenic mice died of rapidly growing melanoma within 12 months after birth, only 8 of the 44 Wv/Wv-RET-transgenic mice developed slowly growing melanocytic tumors with a greatly prolonged mean tumor-free period, 2 of which died of melanoma at a late stage. Even Wv/+-RET-transgenic mice had a clearly prolonged tumor-free period and definitely reduced frequency (6 of 61) of tumor death within 12 months after birth. Melanin production in the skin of these mice was not strongly impaired, suggesting that c-Kit affects the development of melanomas in these mice with only minor effects in melanin production. c-Kit expression in skin soon after birth was promoted in RET-transgenic mice, and c-Kit was expressed at high levels at the benign but not malignant stage of the tumor. A single injection of anti-c-Kit antibody (ACK2) into RET-transgenic mice soon after birth caused a surprisingly long-lasting suppression of development of melanoma, greatly prolonging the tumor-free period, and none of the 28 ACK2-treated RET-transgenic mice died from tumors at 12 months of age. The c-Kit function needed for melanin production was also suppressed for an unusually long time in ACK2-treated, RET-transgenic mice. These results suggest that c-Kit can be a unique target molecule for melanoma treatment.",
author = "Masashi Kato and Kozue Takeda and Yoshiyuki Kawamoto and Toyonori Tsuzuki and Khaled Hossain and Akiko Tamakoshi and Takahiro Kunisada and Yasuhiro Kambayashi and Keiki Ogino and Haruhiko Suzuki and Masahide Takahashi and Izumi Nakashima",
year = "2004",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-03-2532",
language = "English",
volume = "64",
pages = "801--806",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - c-Kit-Targeting Immunotherapy for Hereditary Melanoma in a Mouse Model

AU - Kato, Masashi

AU - Takeda, Kozue

AU - Kawamoto, Yoshiyuki

AU - Tsuzuki, Toyonori

AU - Hossain, Khaled

AU - Tamakoshi, Akiko

AU - Kunisada, Takahiro

AU - Kambayashi, Yasuhiro

AU - Ogino, Keiki

AU - Suzuki, Haruhiko

AU - Takahashi, Masahide

AU - Nakashima, Izumi

PY - 2004/2/1

Y1 - 2004/2/1

N2 - The role of c-Kit in the development of melanoma was studied in line 304/ B6 of RET-transgenic mice, in which melanoma spontaneously develops. In Wv/Wv-RET (304/B6)-transgenic mice, in which c-Kit function was severely impaired, development of melanoma was strongly suppressed. Although 31 of the 44 original RET-transgenic mice died of rapidly growing melanoma within 12 months after birth, only 8 of the 44 Wv/Wv-RET-transgenic mice developed slowly growing melanocytic tumors with a greatly prolonged mean tumor-free period, 2 of which died of melanoma at a late stage. Even Wv/+-RET-transgenic mice had a clearly prolonged tumor-free period and definitely reduced frequency (6 of 61) of tumor death within 12 months after birth. Melanin production in the skin of these mice was not strongly impaired, suggesting that c-Kit affects the development of melanomas in these mice with only minor effects in melanin production. c-Kit expression in skin soon after birth was promoted in RET-transgenic mice, and c-Kit was expressed at high levels at the benign but not malignant stage of the tumor. A single injection of anti-c-Kit antibody (ACK2) into RET-transgenic mice soon after birth caused a surprisingly long-lasting suppression of development of melanoma, greatly prolonging the tumor-free period, and none of the 28 ACK2-treated RET-transgenic mice died from tumors at 12 months of age. The c-Kit function needed for melanin production was also suppressed for an unusually long time in ACK2-treated, RET-transgenic mice. These results suggest that c-Kit can be a unique target molecule for melanoma treatment.

AB - The role of c-Kit in the development of melanoma was studied in line 304/ B6 of RET-transgenic mice, in which melanoma spontaneously develops. In Wv/Wv-RET (304/B6)-transgenic mice, in which c-Kit function was severely impaired, development of melanoma was strongly suppressed. Although 31 of the 44 original RET-transgenic mice died of rapidly growing melanoma within 12 months after birth, only 8 of the 44 Wv/Wv-RET-transgenic mice developed slowly growing melanocytic tumors with a greatly prolonged mean tumor-free period, 2 of which died of melanoma at a late stage. Even Wv/+-RET-transgenic mice had a clearly prolonged tumor-free period and definitely reduced frequency (6 of 61) of tumor death within 12 months after birth. Melanin production in the skin of these mice was not strongly impaired, suggesting that c-Kit affects the development of melanomas in these mice with only minor effects in melanin production. c-Kit expression in skin soon after birth was promoted in RET-transgenic mice, and c-Kit was expressed at high levels at the benign but not malignant stage of the tumor. A single injection of anti-c-Kit antibody (ACK2) into RET-transgenic mice soon after birth caused a surprisingly long-lasting suppression of development of melanoma, greatly prolonging the tumor-free period, and none of the 28 ACK2-treated RET-transgenic mice died from tumors at 12 months of age. The c-Kit function needed for melanin production was also suppressed for an unusually long time in ACK2-treated, RET-transgenic mice. These results suggest that c-Kit can be a unique target molecule for melanoma treatment.

UR - http://www.scopus.com/inward/record.url?scp=10744232280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744232280&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-03-2532

DO - 10.1158/0008-5472.CAN-03-2532

M3 - Article

C2 - 14871802

AN - SCOPUS:10744232280

VL - 64

SP - 801

EP - 806

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 3

ER -